… with locally advanced or metastatic pancreatic cancer has … in patients with advanced pancreatic
cancer. Overall response … docetaxel in advanced and metastatic pancreatic cancer was …

… Risk factors for developing pancreatic cancer include family history, obesity, type 2 diabetes…
present with advanced disease due to lack of or vague symptoms when the cancer is still …

… Pancreatic cancer is the eighth leading cause of cancer-related mortality worldwide. More
than 80% of patients with pancreatic cancer … with locally advanced/metastatic pancreatic …

… The available evidence therefore regards advanced pancreatic cancer as a composite group
in most … Management of comorbidity Pancreatic cancer is characterized by a number of …

… In operated pancreatic cancer patients who are able to begin treatment within 3 months …
The aim of this review is to summarize adjuvant management of resected pancreatic cancer and …

… , it is currently considered the most favorable biomarker for pancreatic cancer management
and treatment evaluation [18]. CA 19-9 should therefore be assessed at baseline, prior (ie, …

… future management strategies for patients with pancreatic cancer. Surgical management …
in the second-line setting of advanced pancreatic cancer management. Two trials assessed the …

… pancreatic cancer. In this highlights article, we will focus on the management of pancreatic
cancer … only drug of choice for the treatment of advanced pancreatic cancer [17]. Numerous …

… Conclusions Gemcitabine plus erlotinib doublet is active in our series of patients with
advanced pancreatic cancer. This study provides efficacy and safety results similar to those of the …

… Again, in this study, CBR was reinforced in the management of pancreatic cancer, which
includes assessment of pain, Karnofsky performance status and weight. A significantly higher …